Resultado de búsqueda
Stay up to date. Looking for our latest news, events or SEC filings? Sign-up for our alerts here. Here you can find all media data in an overview for download. Videos, photos, press releases or data sheets Learn more about BioNTech!
La FDA ha aprobado una EUA para la vacuna bivalente de ARNm contra la COVID-19 (Pfizer-BioNTech) para personas de 6 meses o mayores que no hayan recibido ninguna vacuna previa contra la COVID-19, la cual se administra de la siguiente manera: una serie de 3 dosis para personas de 6 meses a 5 años administradas a las 0, 3 semanas y ...
Comirnaty por BioNTech/Pfizer. Comirnaty funciona preparando al cuerpo para defenderse frente a la COVID-19. Contiene una molécula de ARNm que posee las instrucciones para producir la proteína espícula ( spike protein en inglés). Esta proteína se encuentra en la superficie del virus SARS-CoV-2 y es necesaria para que este pueda entrar en ...
From our roots in Mainz, Germany, we have become a global next-generation immunotherapy company pioneering novel medicines. A global leader in immunotherapy: Our strong international network allows us to consistently pursue our vision of improving the health of people around the world by harnessing the full potential of the immune system.
Prof. Pedro L. Alonso, M.D., Ph.D., joined BioNTech in 2023 as Senior Vice President Science and Medicine and Head of the Global Health Office (GHO). Together with his team, he catalyzes and supports BioNTech’s efforts to apply innovative science in vaccinology to address some of the largest unmet global public health needs, particularly in ...
10 de may. de 2021 · All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. BioNTech Contacts. Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 Media@biontech.de. Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49 6131 9084-0 F: +49 6131 9084-2121 M: service@biontech.de Company About Research & Innovation Pipeline Manufacturing Careers Covid-19 Quick Links Newsroom Investors Healthcare Professionals Connect
